Background: Many validated patient-reported outcome measures (PROMs) evaluate activation, behaviors, and attitudes towards managing one’s own health and care. However, their association with utilization of diabetes management technology and glycemic control has not been well studied.
Methods: People participating in Livongo’s RDMP for 12-18 months were surveyed using 3 validated PROMs that assessed activation (PAM), empowerment (DES), and distress (DDS). Pearson correlation was used to assess the relationship between PROMs and multivariable logistic regression was used to evaluate associations of PROM scores on RDMP usage and A1c improvement overall and by insulin use.
Results: PAM and DES scores were most correlated with each other (r=0.48); neither were associated with A1c improvement. People with higher DES scores were 20% more likely to have high RDMP usage (p<0.05) and people with high RDMP usage were 4.4 times more likely to have A1c improvement. High distress (DDS17>=3) was negatively associated with A1c improvement.
Conclusions: In this study, PAM was not associated with activation, behaviors, and attitudes influencing RDMP usage and outcomes, while the DES and DDS17 were associated with RDMP. Because of the impact of distress on outcomes, it should be monitored and RDMP interventions should focus on distress reduction.
M. Perez-Nieves: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. W. Lu: Employee; Self; Livongo Health. J. Poon: Employee; Self; Eli Lilly and Company. L. Fan: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. R. James: Advisory Panel; Self; AstraZeneca. Employee; Self; Livongo Health. B. Shah: Employee; Self; Livongo Health.
